NCCTG N0872 (Alliance): A Randomized Placebo-Controlled Phase II Trial of Bevacizumab Plus Dasatinib in Patients with Recurrent Glioblastoma (GBM)
      Google Scholar   
Citation:
J Clin Oncol vol 33 (suppl) abstr 2004
Meeting Instance:
ASCO 2015
Year:
2015
Type:
Abstract
Sub type:
Oral
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
3008  
Program:
OGC
Primary Committee:
Neuro-Onc
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA 25224-32, U10CA180821, U10CA180882  
Corr. Author:
 
Authors:
                     
Networks:
LAPS-MN026, LAPS-MO011, METROMIN, RI005, VA009   
Study
NCCTG-N0872
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: